Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19

被引：27

作者：

Zhu, Ke-Wei ^{[1
]}

机构：

[1] Guangzhou Baiyunshan Pharmaceut Holding Co Ltd, Baiyunshan Pharmaceut Gen Factory, Off Pharmacovigilance, Guangzhou 510515, Peoples R China

来源：

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE | 2023年 / 6卷 / 09期

关键词：

Deuremidevir (VV116); simnotrelvir (SIM0417); COVID-19; GS-441524; remdesivir; small-molecule anti-SARS-CoV-2 agent;

D O I：

10.1021/acsptsci.3c00134

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Deuremidevir hydrobromide tablets and simnotrelvir tablets/ritonavir tablets (co-packaged) were approved by the Chinese National Medical Products Administration for the treatment of mild to moderate COVID-19 in January 2023. Both formulations contain small-molecule anti-SARS-CoV-2 agents. Deuremidevir, an oral nucleoside analog, is a broad-spectrum virus replication inhibitor targeting the highly conserved RNA-dependent RNA polymerase. Simnotrelvir-ritonavir is a co-packaged combination drug consisting of simnotrelvir tablets and ritonavir tablets. Simnotrelvir is an oral antiviral agent targeting the 3-chymotrypsin-like protease, which is essential for SARS-CoV-2 viral replication. Previous clinical trials revealed that both deuremidevir and simnotrelvir-ritonavir were effective and well tolerated in the treatment of COVID-19.

引用

页码：1306 / 1309

页数：4

共 16 条

[1] Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir [J].

Akinosoglou, Karolina ;

Schinas, Georgios ;

Gogos, Charalambos .

VIRUSES-BASEL, 2022, 14 (11)

[2]

[Anonymous], CHEMSRC SMART CHEM S

[3] Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease [J].

Avataneo, Valeria ;

de Nicolo, Amedeo ;

Cusato, Jessica ;

Antonucci, Miriam ;

Manca, Alessandra ;

Palermiti, Alice ;

Waitt, Catriona ;

Walimbwa, Stephen ;

Lamorde, Mohammed ;

di Perri, Giovanni ;

D'Avolio, Antonio .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) :1772-1777

[4] VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19 [J].

Cao, Zhujun ;

Gao, Weiyi ;

Bao, Hong ;

Feng, Haiyan ;

Mei, Shuya ;

Chen, Peizhan ;

Gao, Yueqiu ;

Cui, Zhilei ;

Zhang, Qin ;

Meng, Xianmin ;

Gui, Honglian ;

Wang, Weijing ;

Jiang, Yimei ;

Song, Zijia ;

Shi, Yiqing ;

Sun, Jing ;

Zhang, Yifei ;

Xie, Qing ;

Xu, Yiping ;

Ning, Guang ;

Gao, Yuan ;

Zhao, Ren .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (05) :406-417

[5]

Chera Alexandra, 2022, Discoveries (Craiova), V10, pe151, DOI [10.15190/d.2022.10, 10.15190/d.2022.10]

[6] Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and HumansS [J].

Eng, Heather ;

Dantonio, Alyssa L. ;

Kadar, Eugene P. ;

Obach, R. Scott ;

Di, Li ;

Lin, Jian ;

Patel, Nandini C. ;

Boras, Britton ;

Walker, Gregory S. ;

Novak, Jonathan J. ;

Kimoto, Emi ;

Singh, Ravi Shankar P. ;

Kalgutkar, Amit S. .

DRUG METABOLISM AND DISPOSITION, 2022, 50 (05) :576-590

[7]

Han Z.-Y., 2022, VV116 IS APPROVED TR

[8] Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? [J].

Hung, Yuan-Pin ;

Lee, Jen-Chieh ;

Chiu, Chun-Wei ;

Lee, Ching-Chi ;

Tsai, Pei-Jane ;

Hsu, I-Lin ;

Ko, Wen-Chien .

ANTIBIOTICS-BASEL, 2022, 11 (02)

[9]

Junshi Biosciences, Junshi Biosciences announces approval for marketing of VV116 in China

[10]

National Medical Products Administration(NMPA), NAT MED PROD ADM NMP

← 1 2 →